Vitamin D supplementation during TB treatment improves patient symptoms, but does not accelerate the clearance of TB bacteria.

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

COVID-19 was associated with more severe disease outcomes than influenza or RSV during the 2022 to 2023 season.

People still see COVID-19 as an ongoing public health threat, even though the pandemic officially ended in 2023.

For patients with HPV16-positive CIN3, vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness.

Heat-related deaths are expected to climb throughout Europe this century due to climate change, according to study findings.

Among adults hospitalized with influenza, Tamiflu treatment on the day of hospital admission was associated with a reduced risk for disease progression.

Updated recommendations were issued by the IAS-USA regarding the use of ART for treatment and prevention of HIV in adult populations.

Compared with adults aged 65 and older, those aged 18 to 64 are more affected by long COVID neurologic symptoms.

Referral to an infectious disease physician was the only modifiable strategy to reduce 28-day mortality among adults presenting to the ED with bacteremia.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.